DRUG: Saxagliptin and dapagliflozin
Entry
D10826 Mixture Drug
Name
Saxagliptin and dapagliflozin;
Qtern (TN)
Product
QTERN (AstraZeneca Pharmaceuticals LP)
Component
(Saxagliptin [DR:
D08996
] | Saxagliptin hydrate [DR:
D09753
] | Saxagliptin hydrochloride [DR:
D10262
]), (Dapagliflozin [DR:
D08897
] | Dapagliflozin propanediol [DR:
D09763
])
Remark
ATC code:
A10BD21
Product:
D10826<US>
Efficacy
Antidiabetic
Disease
Type 2 diabetes mellitus [DS:
H00409
]
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:
br08303
]
A ALIMENTARY TRACT AND METABOLISM
A10 DRUGS USED IN DIABETES
A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10BD Combinations of oral blood glucose lowering drugs
A10BD21 Saxagliptin and dapagliflozin
D10826 Saxagliptin and dapagliflozin <US>
USP drug classification [BR:
br08302
]
Blood Glucose Regulators
Antidiabetic Combinations
Dapagliflozin/ Saxagliptin
D10826 Saxagliptin and dapagliflozin
New drug approvals in Europe [
br08329.html
]
European public assessment reports (EPAR) authorised medicine
D10826
Other DBs
PubChem:
319902626
LinkDB
» Japanese version
» Back
DBGET
integrated database retrieval system
